Johnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.
Shristi Upadhyay Banskota, MBBS
Advertisement
Articles by Shristi Upadhyay Banskota, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
T-DXd 5.4 mg/kg Combos Yield Fewer Grade ≥3 AEs in HER2+ Gastric Cancers
2
Teclistamab Monotherapy Improves PFS and OS in Relapsed/Refractory Myeloma
3
Enfortumab Vedotin/Pembrolizumab Maintains OS Benefit in Urothelial Carcinoma
4
Personalized Cancer Vaccine/Pembrolizumab Feasible, Effective in Newly Diagnosed GBM
5